Erratum: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Similar Items

• A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
  od: Fava, M, i dr.
  Izdano: (2016)
• A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder
  od: Papakostas, G. I., i dr.
  Izdano: (2019)
• NSI‐189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats
  od: Tajiri, Naoki, i dr.
  Izdano: (2017)
• Enhancement of Mitochondrial Function by the Neurogenic Molecule NSI-189 Accompanies Reversal of Peripheral Neuropathy and Memory Impairment in a Rat Model of Type 2 Diabetes
  od: C. G. Jolivalt, i dr.
  Izdano: (2022-01-01)
• Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189
  od: Jolivalt, Corinne G., i dr.
  Izdano: (2019)